{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:33:07Z","timestamp":1783971187356,"version":"3.55.0"},"reference-count":155,"publisher":"Elsevier","isbn-type":[{"value":"9780128201879","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.apha.2019.12.003","type":"book-chapter","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T18:08:38Z","timestamp":1580148518000},"page":"277-310","source":"Crossref","is-referenced-by-count":50,"title":["M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?"],"prefix":"10.1016","member":"78","reference":[{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/jpet.115.226910","article-title":"Evidence for classical cholinergic toxicity associated with selective activation of M1 muscarinic receptors","volume":"356","author":"Alt","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nature Neuroscience"},{"issue":"Pt. A","key":"10.1016\/bs.apha.2019.12.003_bb0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","article-title":"Therapeutics of Alzheimer's disease: Past, present and future","volume":"76","author":"Anand","year":"2014","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0030","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.neuron.2016.09.006","article-title":"Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline","volume":"91","author":"Ballinger","year":"2016","journal-title":"Neuron"},{"issue":"4558","key":"10.1016\/bs.apha.2019.12.003_bb0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"issue":"5","key":"10.1016\/bs.apha.2019.12.003_bb0040","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2005.01.040","article-title":"Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice","volume":"45","author":"Billings","year":"2005","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1476-5381.1983.tb09388.x","article-title":"The effect of McN-A-343 on muscarinic receptors in the cerebral cortex and heart","volume":"78","author":"Birdsall","year":"1983","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0050","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Archives of Neurology"},{"issue":"Suppl. 4","key":"10.1016\/bs.apha.2019.12.003_bb0055","first-page":"S16","article-title":"The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease","volume":"11","author":"Bodick","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"8","key":"10.1016\/bs.apha.2019.12.003_bb0060","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41418-018-0148-x","article-title":"Alterations in neuronal metabolism contribute to the pathogenesis of prion disease","volume":"25","author":"Bourgognon","year":"2018","journal-title":"Cell Death and Differentiation"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jalz.2012.03.003","article-title":"The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier)","volume":"9","author":"Boxer","year":"2013","journal-title":"Alzheimer's & Dementia"},{"issue":"7","key":"10.1016\/bs.apha.2019.12.003_bb0070","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"The Lancet Neurology"},{"issue":"S165","key":"10.1016\/bs.apha.2019.12.003_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0404.1996.tb05866.x","article-title":"Evolution of the neuropathology of Alzheimer's disease","volume":"94","author":"Braak","year":"1996","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0080","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1172\/JCI87526","article-title":"M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss","volume":"127","author":"Bradley","year":"2017","journal-title":"The Journal of Clinical Investigation"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0085","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/mol.118.111872","article-title":"Bitopic binding mode of an M1 muscarinic acetylcholine receptor agonist associated with adverse clinical trial outcomes","volume":"93","author":"Bradley","year":"2018","journal-title":"Molecular Pharmacology"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0090","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0091-3057(94)00435-L","article-title":"AF150(S): A new functionally selective M1 agonist improves cognitive performance in rats","volume":"51","author":"Brandeis","year":"1995","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"9","key":"10.1016\/bs.apha.2019.12.003_bb0095","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/cb800116f","article-title":"G-protein-coupled receptors: From classical modes of modulation to allosteric mechanisms","volume":"3","author":"Bridges","year":"2008","journal-title":"ACS Chemical Biology"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0100","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1021\/ml100105x","article-title":"Novel N-substituted benzimidazolones as potent, selective, CNS-penetrant, and orally active M1 mAChR agonists","volume":"1","author":"Budzik","year":"2010","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"43","key":"10.1016\/bs.apha.2019.12.003_bb0105","doi-asserted-by":"crossref","first-page":"27765","DOI":"10.1074\/jbc.273.43.27765","article-title":"Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor","volume":"273","author":"Buxbaum","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"issue":"21","key":"10.1016\/bs.apha.2019.12.003_bb0110","doi-asserted-by":"crossref","first-page":"10075","DOI":"10.1073\/pnas.89.21.10075","article-title":"Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta\/A4 amyloid protein precursor","volume":"89","author":"Buxbaum","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/bs.apha.2019.12.003_bb0115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.neuron.2006.01.020","article-title":"M1 receptors play a central role in modulating AD-like pathology in transgenic mice","volume":"49","author":"Caccamo","year":"2006","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","article-title":"International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors","volume":"50","author":"Caulfield","year":"1998","journal-title":"Pharmacological Reviews"},{"issue":"5727","key":"10.1016\/bs.apha.2019.12.003_bb0125","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1126\/science.1108595","article-title":"Allosteric mechanisms of signal transduction","volume":"308","author":"Changeux","year":"2005","journal-title":"Science"},{"key":"10.1016\/bs.apha.2019.12.003_bb0130","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1124\/pr.114.008862","article-title":"International union of basic and clinical pharmacology. XC. Multisite pharmacology: Recommendations for the nomenclature of receptor allosterism and allosteric ligands","volume":"66","author":"Christopoulos","year":"2014","journal-title":"Pharmacological Reviews"},{"issue":"9427","key":"10.1016\/bs.apha.2019.12.003_bb0135","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"issue":"4589","key":"10.1016\/bs.apha.2019.12.003_bb0140","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.6338589","article-title":"Alzheimer's disease: A disorder of cortical cholinergic innervation","volume":"219","author":"Coyle","year":"1983","journal-title":"Science"},{"key":"10.1016\/bs.apha.2019.12.003_bb0145","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer's disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"10.1016\/bs.apha.2019.12.003_bb0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","article-title":"Alzheimer's disease drug development pipeline: 2018","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"8000","key":"10.1016\/bs.apha.2019.12.003_bb0155","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer's disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/bs.apha.2019.12.003_bb0160","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1523\/JNEUROSCI.6393-09.2010","article-title":"Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo","volume":"30","author":"Davis","year":"2010","journal-title":"The Journal of Neuroscience"},{"issue":"15","key":"10.1016\/bs.apha.2019.12.003_bb0165","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1021\/acs.jmedchem.7b00597","article-title":"Design and synthesis of gamma- and delta-lactam M1 positive allosteric modulators (PAMs): Convulsion and cholinergic toxicity of an M1-selective PAM with weak agonist activity","volume":"60","author":"Davoren","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"issue":"13","key":"10.1016\/bs.apha.2019.12.003_bb0170","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1021\/acs.jmedchem.6b00544","article-title":"Discovery of the potent and selective M1 PAM-agonist N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of efficacy and cholinergic side effects","volume":"59","author":"Davoren","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"25","key":"10.1016\/bs.apha.2019.12.003_bb0175","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1523\/JNEUROSCI.0337-12.2012","article-title":"Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models","volume":"32","author":"Digby","year":"2012","journal-title":"The Journal of Neuroscience"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0185","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1152\/physrev.1995.75.2.393","article-title":"The septohippocampal pathway: Structure and function of a central cholinergic system","volume":"75","author":"Dutar","year":"1995","journal-title":"Physiological Reviews"},{"issue":"15","key":"10.1016\/bs.apha.2019.12.003_bb0190","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer's disease","volume":"380","author":"Egan","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/bs.apha.2019.12.003_bb0195","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1021\/acsmedchemlett.8b00261","article-title":"VU6007477, a novel M1 PAM based on a pyrrolo[2,3-b]pyridine carboxamide core devoid of cholinergic adverse events","volume":"9","author":"Engers","year":"2018","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"8","key":"10.1016\/bs.apha.2019.12.003_bb0200","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1096\/fasebj.9.8.7768353","article-title":"Muscarinic acetylcholine receptors: Signal transduction through multiple effectors","volume":"9","author":"Felder","year":"1995","journal-title":"The FASEB Journal"},{"key":"10.1016\/bs.apha.2019.12.003_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apha.2019.04.002","article-title":"GPCR drug discovery-moving beyond the orthosteric to the allosteric domain","volume":"86","author":"Felder","year":"2019","journal-title":"Advances in Pharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40263-016-0399-3","article-title":"Serotonin 5-HT 6 receptor antagonists in Alzheimer's disease: Therapeutic rationale and current development status","volume":"31","author":"Ferrero","year":"2017","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0215","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.nurt.2008.05.002","article-title":"Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease","volume":"5","author":"Fisher","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.apha.2019.12.003_bb0220","first-page":"237","article-title":"M1 muscarinic agonists target major hallmarks of Alzheimer's disease\u2014The pivotal role of brain M1 receptors","volume":"5","author":"Fisher","year":"2008"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0225","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF02244414","article-title":"Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed","volume":"100","author":"Flicker","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.apha.2019.12.003_bb0230","first-page":"183","article-title":"Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia","volume":"10","author":"Foster","year":"2014","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0235","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","article-title":"The G-protein-coupled receptors in the human genome form five main families. phylogenetic analysis, paralogon groups, and fingerprints","volume":"63","author":"Fredriksson","year":"2003","journal-title":"Molecular Pharmacology"},{"issue":"10","key":"10.1016\/bs.apha.2019.12.003_bb0240","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1021\/acs.jmedchem.6b01601","article-title":"Bitopic ligands and metastable binding sites: Opportunities for G protein-coupled receptor (GPCR) medicinal chemistry","volume":"60","author":"Fronik","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0245","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1021\/acschemneuro.8b00402","article-title":"Targeting neuroinflammation as a therapeutic strategy for Alzheimer's disease: Mechanisms, drug candidates, and new opportunities","volume":"10","author":"Fu","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"issue":"10062","key":"10.1016\/bs.apha.2019.12.003_bb0250","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0255","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/(SICI)1096-9861(19990906)411:4<693::AID-CNE13>3.0.CO;2-D","article-title":"Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease","volume":"411","author":"Gilmor","year":"1999","journal-title":"Journal of Comparative Neurology"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer's disease in clinical trials","volume":"68","author":"Gody\u0144","year":"2016","journal-title":"Pharmacological Reports"},{"issue":"11","key":"10.1016\/bs.apha.2019.12.003_bb0265","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1073\/pnas.85.11.4051","article-title":"Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau","volume":"85","author":"Goedert","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"23","key":"10.1016\/bs.apha.2019.12.003_bb0270","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"issue":"4693","key":"10.1016\/bs.apha.2019.12.003_bb0275","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.2858129","article-title":"Alterations in L-glutamate binding in Alzheimer's and Huntington's diseases","volume":"227","author":"Greenamyre","year":"1985","journal-title":"Science"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0280","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/157015907781695946","article-title":"Allosteric modulation of muscarinic acetylcholine receptors","volume":"5","author":"Gregory","year":"2007","journal-title":"Current Neuropharmacology"},{"issue":"13","key":"10.1016\/bs.apha.2019.12.003_bb0285","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","article-title":"Microtubule-associated protein tau. A component of Alzheimer paired helical filaments","volume":"261","author":"Grundke-Iqbal","year":"1986","journal-title":"Journal of Biological Chemistry"},{"issue":"13","key":"10.1016\/bs.apha.2019.12.003_bb0290","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7386","key":"10.1016\/bs.apha.2019.12.003_bb0295","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10753","article-title":"Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist","volume":"482","author":"Haga","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0300","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jalz.2017.11.009","article-title":"AF710B, an M1\/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease","volume":"14","author":"Hall","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/bs.apha.2019.12.003_bb0305","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer's disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends in Pharmacological Sciences"},{"issue":"5054","key":"10.1016\/bs.apha.2019.12.003_bb0310","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"5","key":"10.1016\/bs.apha.2019.12.003_bb0315","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1046\/j.1471-4159.1998.71052094.x","article-title":"Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion","volume":"71","author":"Haring","year":"1998","journal-title":"Journal of Neurochemistry"},{"issue":"9","key":"10.1016\/bs.apha.2019.12.003_bb0320","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1364-6613(99)01365-0","article-title":"Neuromodulation: Acetylcholine and memory consolidation","volume":"3","author":"Hasselmo","year":"1999","journal-title":"Trends in Cognitive Sciences"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0325","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.conb.2006.09.002","article-title":"The role of acetylcholine in learning and memory","volume":"16","author":"Hasselmo","year":"2006","journal-title":"Current Opinion in Neurobiology"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0330","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/0166-2236(93)90159-J","article-title":"Acetylcholine and memory","volume":"16","author":"Hasselmo","year":"1993","journal-title":"Trends in Neurosciences"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0335","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/npp.2010.104","article-title":"Modes and models of forebrain cholinergic neuromodulation of cognition","volume":"36","author":"Hasselmo","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.apha.2019.12.003_bb0340","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nature Reviews Drug Discovery"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0345","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"The Lancet Neurology"},{"key":"10.1016\/bs.apha.2019.12.003_bb0350","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1749-6632.2000.tb06937.x","article-title":"Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease","volume":"920","author":"Hock","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0355","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0360","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bmcl.2018.12.049","article-title":"New evolutions in the BACE1 inhibitor field from 2014 to 2018","volume":"29","author":"Hsiao","year":"2019","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0365","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1146\/annurev.pa.30.040190.003221","article-title":"Muscarinic receptor subtypes","volume":"30","author":"Hulme","year":"1990","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0370","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000115115.98960.37","article-title":"Early A\u03b2 accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain","volume":"62","author":"Ingelsson","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/bs.apha.2019.12.003_bb0375","first-page":"45","article-title":"The tolerability and safety of cholinesterase inhibitors in the treatment of dementia","volume":"127","author":"Inglis","year":"2002","journal-title":"International Journal of Clinical Practice. Supplement"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0380","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","article-title":"Tau and neurodegenerative disease: The story so far","volume":"12","author":"Iqbal","year":"2016","journal-title":"Nature Reviews. Neurology"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0385","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrn2967","article-title":"Amyloid-beta and tau\u2014A toxic pas de deux in Alzheimer's disease","volume":"12","author":"Ittner","year":"2011","journal-title":"Nature Reviews. Neuroscience"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0390","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ana.22628","article-title":"An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease","volume":"71","author":"Jack","year":"2012","journal-title":"Annals of Neurology"},{"issue":"41","key":"10.1016\/bs.apha.2019.12.003_bb0395","doi-asserted-by":"crossref","first-page":"10422","DOI":"10.1523\/JNEUROSCI.1850-08.2008","article-title":"Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats","volume":"28","author":"Jones","year":"2008","journal-title":"The Journal of Neuroscience"},{"issue":"34","key":"10.1016\/bs.apha.2019.12.003_bb0400","doi-asserted-by":"crossref","first-page":"23817","DOI":"10.1074\/jbc.M114.582874","article-title":"Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor","volume":"289","author":"Keov","year":"2014","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0405","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1124\/mol.113.087320","article-title":"Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M(1) muscarinic acetylcholine receptor","volume":"84","author":"Keov","year":"2013","journal-title":"Molecular Pharmacology"},{"issue":"Pt. 16","key":"10.1016\/bs.apha.2019.12.003_bb0410","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1242\/jcs.00643","article-title":"Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes","volume":"116","author":"Kinoshita","year":"2003","journal-title":"Journal of Cell Science"},{"issue":"7386","key":"10.1016\/bs.apha.2019.12.003_bb0415","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature10867","article-title":"Structure and dynamics of the M3 muscarinic acetylcholine receptor","volume":"482","author":"Kruse","year":"2012","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2019.12.003_bb0420","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd4295","article-title":"Muscarinic acetylcholine receptors: Novel opportunities for drug development","volume":"13","author":"Kruse","year":"2014","journal-title":"Nature Reviews Drug Discovery"},{"issue":"7478","key":"10.1016\/bs.apha.2019.12.003_bb0425","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12735","article-title":"Activation and allosteric modulation of a muscarinic acetylcholine receptor","volume":"504","author":"Kruse","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.apha.2019.12.003_bb0430","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00005072-199808000-00001","article-title":"Pharmacological drug treatment of Alzheimer disease: The cholinergic hypothesis revisited","volume":"57","author":"Ladner","year":"1998","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"issue":"7","key":"10.1016\/bs.apha.2019.12.003_bb0435","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1073\/pnas.96.7.3922","article-title":"Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease","volume":"96","author":"Lammich","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0440","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tips.2012.10.003","article-title":"Bridging the gap: Bitopic ligands of G-protein-coupled receptors","volume":"34","author":"Lane","year":"2013","journal-title":"Trends in Pharmacological Sciences"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0445","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/jpet.115.226712","article-title":"The M1 muscarinic positive allosteric modulator PQCA improves performance on translatable tests of memory and attention in rhesus monkeys","volume":"355","author":"Lange","year":"2015","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0450","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1124\/mol.105.017814","article-title":"Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M 1 receptor: Direct pharmacological evidence that AC-42 is an allosteric agonist","volume":"69","author":"Langmead","year":"2006","journal-title":"Molecular Pharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0455","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1021\/cn900003h","article-title":"Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system","volume":"1","author":"Lebois","year":"2010","journal-title":"ACS Chemical Neuroscience"},{"issue":"21","key":"10.1016\/bs.apha.2019.12.003_bb0460","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1016\/j.bmcl.2011.08.084","article-title":"Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071","volume":"21","author":"Lebois","year":"2011","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0465","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1021\/acschemneuro.6b00278","article-title":"Disease-modifying effects of M1 muscarinic acetylcholine receptor activation in an Alzheimer's disease mouse model","volume":"8","author":"Lebois","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"issue":"10","key":"10.1016\/bs.apha.2019.12.003_bb0470","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1021\/acschemneuro.6b00160","article-title":"Effects of selective M1 muscarinic receptor activation on hippocampal spatial representations and neuronal oscillations","volume":"7","author":"Lebois","year":"2016","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.apha.2019.12.003_bb0475","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3389\/fimmu.2019.00585","article-title":"Forebrain cholinergic signaling regulates innate immune responses and inflammation","volume":"10","author":"Lehner","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"5\u20136","key":"10.1016\/bs.apha.2019.12.003_bb0480","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0024-3205(93)90300-R","article-title":"Immunological localization of m1\u2013m5 muscarinic acetylcholine receptors in peripheral tissues and brain","volume":"52","author":"Levey","year":"1993","journal-title":"Life Sciences"},{"issue":"24","key":"10.1016\/bs.apha.2019.12.003_bb0485","doi-asserted-by":"crossref","first-page":"13541","DOI":"10.1073\/pnas.93.24.13541","article-title":"Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimerdisease","volume":"93","author":"Levey","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"10","key":"10.1016\/bs.apha.2019.12.003_bb0490","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991","article-title":"Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies","volume":"11","author":"Levey","year":"1991","journal-title":"The Journal of Neuroscience"},{"issue":"37","key":"10.1016\/bs.apha.2019.12.003_bb0495","doi-asserted-by":"crossref","first-page":"15950","DOI":"10.1073\/pnas.0900903106","article-title":"Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation","volume":"106","author":"Ma","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0500","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/mol.108.052886","article-title":"Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity","volume":"75","author":"Marlo","year":"2009","journal-title":"Molecular Pharmacology"},{"issue":"12","key":"10.1016\/bs.apha.2019.12.003_bb0505","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2019.12.003_bb9153","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2013.01.009","article-title":"Hippocampal G\u03b1q\/\u2081\u2081 but not G\u03b1o-coupled receptors are altered in aging","volume":"70","author":"McQuail","year":"2013","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0510","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ajpath.2011.04.041","article-title":"Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline","volume":"179","author":"Medeiros","year":"2011","journal-title":"The American Journal of Pathology"},{"issue":"23\u201324","key":"10.1016\/bs.apha.2019.12.003_bb0515","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.drudis.2013.09.005","article-title":"Allosteric modulation of the M1 muscarinic acetylcholine receptor: Improving cognition and a potential treatment for schizophrenia and Alzheimer's disease","volume":"18","author":"Melancon","year":"2013","journal-title":"Drug Discovery Today"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0520","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0006-8993(85)91228-4","article-title":"Galanin-like immunoreactivity in cholinergic neurons of the septum-basal forebrain complex projecting to the hippocampus of the rat","volume":"360","author":"Melander","year":"1985","journal-title":"Brain Research"},{"key":"10.1016\/bs.apha.2019.12.003_bb0525","series-title":"Progress in brain research","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0079-6123(03)45004-8","article-title":"The cholinergic innervation of the human cerebral cortex","volume":"Vol. 145","author":"Mesulam","year":"2004"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0530","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cne.902140206","article-title":"Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey","volume":"214","author":"Mesulam","year":"1983","journal-title":"Journal of Comparative Neurology"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0535","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.20100","article-title":"Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum","volume":"55","author":"Mesulam","year":"2004","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0540","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/acs.jmedchem.5b01562","article-title":"4-Phenylpyridin-2-one derivatives: A novel class of positive allosteric modulator of the M1 muscarinic acetylcholine receptor","volume":"59","author":"Mistry","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1016\/bs.apha.2019.12.003_bb0545","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1021\/acschemneuro.8b00106","article-title":"PF-06827443 displays robust allosteric agonist and positive allosteric modulator activity in high receptor reserve and native systems","volume":"9","author":"Moran","year":"2018","journal-title":"ACS Chemical Neuroscience"},{"issue":"8","key":"10.1016\/bs.apha.2019.12.003_bb0550","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/s41386-018-0033-9","article-title":"M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition","volume":"43","author":"Moran","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0555","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0014-4886(89)90124-6","article-title":"Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain","volume":"105","author":"Mufson","year":"1989","journal-title":"Experimental Neurology"},{"issue":"5","key":"10.1016\/bs.apha.2019.12.003_bb0560","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000107329","article-title":"Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the Stria terminalis in aging, Alzheimer's disease and down's syndrome (Part 1 of 2)","volume":"4","author":"Mufson","year":"1993","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0565","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1017\/S1461145712000752","article-title":"The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction","volume":"16","author":"Nathan","year":"2013","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0570","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.ne.10.030187.001211","article-title":"Molecular properties of the muscarinic acetylcholine receptor","volume":"10","author":"Nathanson","year":"1987","journal-title":"Annual Review of Neuroscience"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0575","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/msj.20279","article-title":"Alzheimer's disease: Diagnosis and treatment across the spectrum of disease severity","volume":"78","author":"Neugroschl","year":"2011","journal-title":"Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2019.12.003_bb0580","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/1531-8249(200012)48:6<913::AID-ANA12>3.0.CO;2-S","article-title":"The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease","volume":"48","author":"Nitsch","year":"2000","journal-title":"Annals of Neurology"},{"issue":"5080","key":"10.1016\/bs.apha.2019.12.003_bb0585","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/science.1411529","article-title":"Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors","volume":"258","author":"Nitsch","year":"1992","journal-title":"Science"},{"issue":"8004","key":"10.1016\/bs.apha.2019.12.003_bb0590","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(77)91780-9","article-title":"Necropsy evidence of central cholinergic deficits in senile dementia","volume":"1","author":"Perry","year":"1977","journal-title":"Lancet"},{"issue":"6150","key":"10.1016\/bs.apha.2019.12.003_bb0595","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/bmj.2.6150.1457","article-title":"Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia","volume":"2","author":"Perry","year":"1978","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0600","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/acschemneuro.8b00496","article-title":"In vivo modulation of hippocampal excitability by M4 muscarinic acetylcholine receptor activator: Implications for treatment of Alzheimer's disease and schizophrenic patients","volume":"10","author":"Popiolek","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.apha.2019.12.003_bb0605","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2015.03.029","article-title":"The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model","volume":"287","author":"Puri","year":"2015","journal-title":"Behavioural Brain Research"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0610","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/ana.410200407","article-title":"Neurofibrillary degeneration of cholinergic and noncholinergic neurons of the basal forebrain in Alzheimer's disease","volume":"20","author":"Rasool","year":"1986","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0615","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1021\/acschemneuro.6b00429","article-title":"Diverse effects on M1 signaling and adverse effect liability within a series of M1 Ago-PAMs","volume":"8","author":"Rook","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"issue":"9","key":"10.1016\/bs.apha.2019.12.003_bb0620","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1021\/acschemneuro.8b00131","article-title":"A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity","volume":"9","author":"Rook","year":"2018","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.apha.2019.12.003_bb0625","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0022-3565(25)26023-2","article-title":"An unusual type of sympathetic ganglionic stimulant","volume":"132","author":"Roszkowski","year":"1961","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0630","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00177553","article-title":"The effects of scopolamine on working memory in healthy young volunteers","volume":"96","author":"Rusted","year":"1988","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0635","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0165-0173(96)00009-4","article-title":"Cognitive functions of cortical acetylcholine: Toward a unifying hypothesis","volume":"23","author":"Sarter","year":"1997","journal-title":"Brain Research Reviews"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0640","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbr.2010.11.058","article-title":"The cholinergic system in aging and neuronal degeneration","volume":"221","author":"Schliebs","year":"2011","journal-title":"Behavioural Brain Research"},{"issue":"5","key":"10.1016\/bs.apha.2019.12.003_bb0645","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/scientificamerican1191-68","article-title":"Amyloid protein and Alzheimer's disease","volume":"265","author":"Selkoe","year":"1991","journal-title":"Scientific American"},{"issue":"4","key":"10.1016\/bs.apha.2019.12.003_bb0650","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer's disease","volume":"6","author":"Selkoe","year":"1991","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/bs.apha.2019.12.003_bb0655","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"The American Journal of Psychiatry"},{"issue":"45","key":"10.1016\/bs.apha.2019.12.003_bb0660","doi-asserted-by":"crossref","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","article-title":"A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning","volume":"29","author":"Shirey","year":"2009","journal-title":"The Journal of Neuroscience"},{"issue":"8","key":"10.1016\/bs.apha.2019.12.003_bb0665","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1517\/17460441.2011.586691","article-title":"Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors","volume":"6","author":"Stallaert","year":"2011","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0670","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0006-8993(92)91541-L","article-title":"Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists","volume":"596","author":"Svensson","year":"1992","journal-title":"Brain Research"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0675","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1006\/exnr.2000.7380","article-title":"Alzheimer-related \u03c4-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia","volume":"163","author":"Thal","year":"2000","journal-title":"Experimental Neurology"},{"issue":"7594","key":"10.1016\/bs.apha.2019.12.003_bb0680","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature17188","article-title":"Crystal structures of the M1 and M4 muscarinic acetylcholine receptors","volume":"531","author":"Thal","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2019.12.003_bb0685","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrn2977","article-title":"The role of G protein-coupled receptors in the pathology of Alzheimer's disease","volume":"12","author":"Thathiah","year":"2011","journal-title":"Nature Reviews Neuroscience"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0690","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/jpet.109.160242","article-title":"Contrasting effects of allosteric and orthosteric agonists on M(1) muscarinic acetylcholine receptor internalization and down-regulation","volume":"331","author":"Thomas","year":"2009","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0695","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/acschemneuro.8b00625","article-title":"Striatal, hippocampal, and cortical networks are differentially responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline","volume":"10","author":"Thorn","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.apha.2019.12.003_bb9154","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.neurobiolaging.2005.07.010","article-title":"Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease","volume":"9","author":"Tsang","year":"2006","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0700","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00213-012-2788-8","article-title":"The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque","volume":"225","author":"Uslaner","year":"2013","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2019.12.003_bb0705","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.117.245894","article-title":"Preclinical to human translational pharmacology of the novel M1 positive allosteric modulator MK-7622","volume":"365","author":"Uslaner","year":"2018","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"43","key":"10.1016\/bs.apha.2019.12.003_bb0710","doi-asserted-by":"crossref","first-page":"29312","DOI":"10.1074\/jbc.M803801200","article-title":"A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric\/allosteric ligand","volume":"283","author":"Valant","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"issue":"11","key":"10.1016\/bs.apha.2019.12.003_bb0715","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00213-014-3813-x","article-title":"Improved cognition without adverse effects: Novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey","volume":"232","author":"Vardigan","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.apha.2019.12.003_bb0720","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature11896","article-title":"Molecular signatures of G-protein-coupled receptors","volume":"494","author":"Venkatakrishnan","year":"2013","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2019.12.003_bb0725","series-title":"Progress in brain research","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0079-6123(03)45003-6","article-title":"Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus","volume":"Vol. 145","author":"Volpicelli","year":"2004"},{"key":"10.1016\/bs.apha.2019.12.003_bb0730","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","article-title":"Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease","volume":"4","author":"Voss","year":"2018","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"key":"10.1016\/bs.apha.2019.12.003_bb0735","series-title":"Crystal structure of the M5 muscarinic acetylcholine receptor","first-page":"730622","author":"Vuckovic","year":"2019"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0740","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.111.182063","article-title":"Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist","volume":"338","author":"Watt","year":"2011","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"8","key":"10.1016\/bs.apha.2019.12.003_bb0745","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0165-6147(93)90049-P","article-title":"Molecular basis of muscarinic receptor function","volume":"14","author":"Wess","year":"1993","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"10.1016\/bs.apha.2019.12.003_bb0750","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.410100203","article-title":"Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis","volume":"10","author":"Whitehouse","year":"1981","journal-title":"Annals of Neurology"},{"issue":"4537","key":"10.1016\/bs.apha.2019.12.003_bb0755","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.apha.2019.12.003_bb0760","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose leuco-methylthioninium bis (hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: Cohort analysis as modified primary outcome in a phase III clinical trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"Journal of Alzheimer's Disease"},{"issue":"29","key":"10.1016\/bs.apha.2019.12.003_bb0765","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1523\/JNEUROSCI.1744-05.2005","article-title":"Age-associated alterations of hippocampal place cells are subregion specific","volume":"25","author":"Wilson","year":"2005","journal-title":"The Journal of Neuroscience"},{"issue":"7","key":"10.1016\/bs.apha.2019.12.003_bb0770","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1046\/j.1460-9568.2003.02588.x","article-title":"Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity","volume":"17","author":"Bymaster","year":"2003","journal-title":"European Journal of Neuroscience"}],"container-title":["Advances in Pharmacology","From Structure to Clinical Development: Allosteric Modulation of G Protein-Coupled Receptors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358919300730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358919300730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:44:19Z","timestamp":1760960659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358919300730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128201879"],"references-count":155,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2019.12.003","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}